BIOCARDIA INC BCDA 深 滬
等待開盤 10-24 09:30:00 美东时间
1.38
-0.080
-5.48%
華盛通- 最 高1.51
- 今 開1.46
- 成交量 25.69万股
- 最 低 1.35
- 昨 收 1.46
- 總市值 1464.00万
- 52周最高 3.20
- 市盈率 靜 --
- 換手率 0.00%
- 52周最低 1.00
- 委 比 68.67%
- 總股本 1060.87万
- 歷史最高 129.00
- 量 比 2.58
- 振 幅 10.96%
- 歷史最低 1.00
- 每 手 1
- 風險率 0.36%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多BioCardia Sets Record Date for Annual Meeting
BioCardia ( ($BCDA) ) just unveiled an announcement. BioCardia, Inc. has announ...
10-08 04:52
BioCardia regains Nasdaq compliance after balance sheet improvements; shares up
BioCardia (NASDAQ:BCDA) has regained compliance with Nasdaq listing requirements. On October 1, 2025, Nasdaq confirmed BioCardia now meets the Equity Rule. Compliance follows efforts to strengthen the...
10-02 20:23
BioCardia Regains Compliance With Nasdaq Listing Requirements
BioCardia, Inc. (NASDAQ:BCDA), a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, announces it has regained compliance with the Nasdaq Capital Market's
10-02 20:04
美股大行评级 | 潜在涨幅1650.0%！Ascendiant Capital维持GRI Bio"买入"评级，目标价上调至35美元
今日重点评级关注：Ascendiant Capital：维持GRI Bio"买入"评级，目标价从34美元升至35美元；Ascendiant Capital：维持Atossa Therapeutics"买入"评级，目标价从7.5美元升至7.75美元
09-23 09:52
BioCardia Announces Positive Preliminary Clinical Consultation with Japan Pharmaceutical and Medical Device Agency on Cell Therapy for Ischemic Heart Failure
<p>BioCardia announced positive preliminary clinical consultation with Japan’s PMDA regarding the CardiAMP Heart Failure Trial results. PMDA requested additional details, including clarifications on composite endpoints, statistical power, NTproBNP subgroup rationale, patient target numbers in Japan, and clinical development status in the U.S. BioCardia is preparing responses with formal consultation expected near year-end. CEO Peter Altman expres...
09-22 12:00
BioCardia Raises $5.1 Million Through Stock Sale
BioCardia ( ($BCDA) ) has provided an update. On September 19, 2025, BioCardia,...
09-20 00:47
BioCardia Announces $6 Million Public Offering
An update from BioCardia ( ($BCDA) ) is now available. On September 18, 2025, B...
09-18 21:50
BioCardia Announces CardiAMP Chronic Myocardial Ischemia Trial Top Line Data of Roll-in Cohort Show Improved Exercise Tolerance and Reduced Angina Episodes at Six-Month Primary Follow-up
BioCardia, Inc. announced positive results from its open-label CardiAMP Cell Therapy trial for patients with chronic myocardial ischemia and refractory angina. The minimally invasive therapy showed significant improvement, with patients experiencing an average 80-second increase in exercise tolerance and an 82% reduction in angina episodes at six months. These results outperform existing FDA-approved treatments like Ranolazine and EECP. CardiAMP ...
09-18 11:00
BioCardia CEO Peter Altman to Present at the H. C. Wainwright 27th Annual Global Investment Conference in New York City September 8-10, 2025
Peter Altman, PhD., President and CEO of BioCardia, Inc., will present a corporate update at the H. C. Wainwright 27th Annual Global Investment Conference in New York City on September 10, 2025. His presentation will include recent progress on the company’s clinical cell therapy programs for ischemic heart disease, regulatory activities for CardiAMP® cell therapy and the Helix™ delivery catheter, and updates on partnerships and funding for the Ca...
09-04 13:00
